UNSPSC 51111911: Porfimer

This classification denotes a photosensitizing agent with the molecular formula (C34H36N4O5)n.(C34H34N4O4)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M15H03K69B, chemically known as 21h,23h-porphine-2,18-dipropanoic acid, 7-(1-(1-(8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21h,23h-porphin-2-yl)ethoxy)ethyl)-12-(1-hydroxyethyl)-3,8,13,17-tetramethyl- but generally known as porfimer, which bears US NIH Compound Identifier 57166.

UNSPSC 51111911 Porfimer, a Commodity code, covers pharmaceutical products and related dispensing services procured by state and local health agencies for pharmacy benefit programs and direct-to-manufacturer prescription fulfillment initiatives. State and local governments use this code to source prescription pharmaceuticals, including branded and generic medications, through various contracting models — traditional pharmacy benefit manager arrangements, direct-to-manufacturer relationships, and value-based or outcomes-based agreements that tie pricing and performance to clinical or cost metrics. Issuing bodies include state health and human services departments, state employee health plans, and other public sector health benefit programs seeking to optimize prescription drug costs and access. The work typically involves vendor capacity to manage product volume, negotiate pricing models, and administer fulfillment logistics across multiple beneficiary populations and geographic service areas.

The Texas Health and Human Services Commission posted a Request for Information (RFI) No. HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling near-term procurement activity in Texas. The RFI solicits information from vendors with experience in direct contracting for self-insured employers and health plans, flexibility to negotiate net pricing models, and capacity to implement value-based agreements. No formal award timeline, funding level, or evaluation criteria were specified in the RFI; the state indicated it would use vendor responses to develop detailed procurement specifications and implementation timelines for subsequent formal solicitations. This represents exploratory procurement activity in advance of a formal RFP, suggesting that vendors with direct-to-manufacturer pharmacy relationships and experience in outcomes-based contracting should monitor Texas HHS procurement notices for the follow-on competitive solicitation.